Tracking a Moving Target in HR+ Metastatic Breast Cancer: Innovative Oral Therapies and Evolving Strategies

This activity was originally presented at the 2025 HOPA Annual Conference in Portland, Oregon.

Program Description

Though targeted therapies have contributed to more personalized treatment decisions for patients with breast cancer, resistance to endocrine therapy and adverse effects (AEs) remain challenges. AEs pose a major challenge in breast cancer treatment adherence, with surveys showing that a majority of patients experience AEs, leading to early discontinuation in one-third of cases. This session will explore the emergence of oral selective estrogen receptor degraders (SERDs) and targeted therapies in the treatment of hormone receptor-positive (HR+)/HER2-negative breast cancer, with the latest insights into optimizing treatment for patients. Interactive patient case reviews will provide practical strategies for patient identification, sequencing therapies, managing AEs, and integrating oral regimens into clinical practice. The clinical evidence behind frontline triplet regimens, individualized treatment selection, and the emerging role of oral SERDs and integrating these emerging therapies into breast cancer care practices will be reviewed.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 17, 2025
Expiration date: April 17, 2026

Time to complete activity: 1.0 hours

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
• Apply drug therapy expertise and patient-specific characteristics to individualized treatment decisions for patients with HR+/HER2-negative metastatic breast cancer
• Employ effective strategies for managing adverse effects of novel therapies in HR+ metastatic breast cancer to support treatment adherence and improve patient quality of life

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-25-114-H01-P. The activity is available for CE credit through April 17, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Megan May, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Amgen Inc, Lilly; Speakers Bureau: Amgen Inc, AstraZeneca

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Allison R. Butts, PharmD, BCOP; and Helen K. Chew, MD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms